当前位置: 首页 >> 检索结果
681. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia.
作者: Mary P Bronner.;Bergein F Overholt.;Shari L Taylor.;Rodger C Haggitt.;Kenneth K Wang.;J Steven Burdick.;Charles J Lightdale.;Michael Kimmey.;Hector R Nava.;Michael V Sivak.;Norman Nishioka.;Hugh Barr.;Marcia I Canto.;Norman Marcon.;Marcos Pedrosa.;Michael Grace.;Michelle Depot.; .
来源: Gastroenterology. 2009年136卷1期56-64; quiz 351-2页
Photodynamic therapy with porfimer sodium combined with acid suppression (PHOPDT) is used to treat patients with Barrett's esophagus (BE) with high-grade dysplasia (HGD). A 5-year phase 3 trial was conducted to determine the extent of squamous overgrowth of BE with HGD after PHOPDT.
682. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
作者: James J Farrell.;Hany Elsaleh.;Miguel Garcia.;Raymond Lai.;Ali Ammar.;William F Regine.;Ross Abrams.;A Bowen Benson.;John Macdonald.;Carol E Cass.;Adam P Dicker.;John R Mackey.
来源: Gastroenterology. 2009年136卷1期187-95页
The human equilibrative nucleoside transporter (hENT1) protein transports gemcitabine into cells. Small retrospective studies in pancreatic cancer suggest that levels of hENT1 protein or messenger RNA may have prognostic value. We studied the predictive value of hENT1 levels in a cohort of pancreatic adenocarcinoma patients from the large prospective randomized adjuvant treatment trial RTOG9704.
683. A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis.
作者: Payal Bhardwaj.;Pramod Kumar Garg.;Subir Kumar Maulik.;Anoop Saraya.;Rakesh Kumar Tandon.;Subrat Kumar Acharya.
来源: Gastroenterology. 2009年136卷1期149-159.e2页
Oxidative stress has been implicated in the pathophysiology of chronic pancreatitis (CP). We evaluated the effects of antioxidant supplementation on pain relief, oxidative stress, and antioxidant status in patients with CP.
684. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.
作者: Stephan Miehlke.;Ahmed Madisch.;Birgit Bethke.;Andrea Morgner.;Eberhard Kuhlisch.;Christine Henker.;Gerfried Vogel.;Matthias Andersen.;Eberhard Meier.;Gustavo Baretton.;Manfred Stolte.
来源: Gastroenterology. 2008年135卷5期1510-6页
Oral budesonide effectively induces clinical remission in patients with collagenous colitis, a debilitating illness characterized by chronic watery/loose diarrhea, but there is a high rate of relapse after treatment cessation.
685. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.
作者: Nicholas C Boetticher.;Craig J Peine.;Paul Kwo.;Gary A Abrams.;Tushar Patel.;Bashar Aqel.;Lisa Boardman.;Gregory J Gores.;William S Harmsen.;Craig J McClain.;Patrick S Kamath.;Vijay H Shah.
来源: Gastroenterology. 2008年135卷6期1953-60页
Alcoholic hepatitis is a cause of major morbidity and mortality that lacks effective therapies. Both experimental and clinical evidence indicate that the multifunctional cytokine tumor necrosis factor-alpha (TNF-alpha) contributes to pathogenesis and clinical sequelae of alcoholic hepatitis. A pilot study demonstrated that the TNF-alpha-neutralizing molecule etanercept could be an effective treatment for patients with alcoholic hepatitis.
686. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
作者: Brian G Feagan.;Remo Panaccione.;William J Sandborn.;Geert R D'Haens.;Stefan Schreiber.;Paul J Rutgeerts.;Edward V Loftus.;Kathleen G Lomax.;Andrew P Yu.;Eric Q Wu.;Jingdong Chao.;Parvez Mulani.
来源: Gastroenterology. 2008年135卷5期1493-9页
We determined the effects of adalimumab maintenance treatment on the risks of hospitalization and surgery in Crohn's disease (CD).
687. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
作者: Loren Laine.;Sean P Curtis.;Michael Langman.;Dennis M Jensen.;Byron Cryer.;Amarjot Kaur.;Christopher P Cannon.
来源: Gastroenterology. 2008年135卷5期1517-25页
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause lower gastrointestinal (GI) clinical events such as bleeding. Cyclo-oxygenase (COX)-2 selective inhibitors decrease upper GI events, but no prospective trial has prespecified assessment of lower GI clinical events.
688. Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children.
作者: Shafiqul A Sarker.;Hasan Mahmud.;Lena Davidsson.;Nur H Alam.;Tahmeed Ahmed.;Nurul Alam.;Mohammed A Salam.;Christoph Beglinger.;Niklaus Gyr.;George J Fuchs.
来源: Gastroenterology. 2008年135卷5期1534-42页
We investigated Helicobacter pylori (H pylori)-infection as a cause of iron deficiency (ID) and iron-deficiency anemia (IDA) or treatment failure of iron supplementation.
689. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial.
作者: Geert R D'Haens.;Severine Vermeire.;Gert Van Assche.;Maja Noman.;Isolde Aerden.;Gust Van Olmen.;Paul Rutgeerts.
来源: Gastroenterology. 2008年135卷4期1123-9页
More than 80% of Crohn's disease (CD) patients undergoing resection suffer recurrence of their disease. Therapy with aminosalicylates, antimetabolites, or antibiotics leads to a modest reduction in the incidence of recurrence.
690. Impact of wide-angle, high-definition endoscopy in the diagnosis of colorectal neoplasia: a randomized controlled trial.
作者: Maria Pellisé.;Glòria Fernández-Esparrach.;Andrés Cárdenas.;Oriol Sendino.;Elena Ricart.;Eva Vaquero.;Antonio Z Gimeno-García.;Cristina Rodríguez de Miguel.;Michel Zabalza.;Angels Ginès.;Josep M Piqué.;Josep Llach.;Antoni Castells.
来源: Gastroenterology. 2008年135卷4期1062-8页
It is essential to optimize standard colonoscopy technique to be able to increase polyp detection. We sought to compare the performance of colonoscopy using a high-definition, wide-angle endoscope (HDE) versus a standard colonoscope (SC) for the detection of colorectal neoplasia.
691. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
作者: April B M Grudell.;Seth Sweetser.;Michael Camilleri.;Deborah J Eckert.;Maria I Vazquez-Roque.;Paula J Carlson.;Duane D Burton.;Autumn E Braddock.;Matthew M Clark.;Karen M Graszer.;Sarah A Kalsy.;Alan R Zinsmeister.
来源: Gastroenterology. 2008年135卷4期1142-54页
Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate alpha2A adrenoreceptor, 5-HT transporter, and GNbeta3 genes and weight loss with sibutramine.
692. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
作者: Guruprasad P Aithal.;James A Thomas.;Philip V Kaye.;Adam Lawson.;Stephen D Ryder.;Ian Spendlove.;Andrew S Austin.;Jan G Freeman.;Linda Morgan.;Jonathan Webber.
来源: Gastroenterology. 2008年135卷4期1176-84页
Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available. Insulin sensitizing, anti-inflammatory, and antifibrotic properties of thiazolidinediones support their use in treating NASH. We have evaluated pioglitazone in the treatment of nondiabetic patients with NASH.
693. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
作者: William J Sandborn.;Brian G Feagan.;Richard N Fedorak.;Ellen Scherl.;Mark R Fleisher.;Seymour Katz.;Jewel Johanns.;Marion Blank.;Paul Rutgeerts.; .
来源: Gastroenterology. 2008年135卷4期1130-41页
Interleukin-12 and interleukin-23 are inflammatory cytokines implicated in Crohn's disease pathophysiology. Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin-12/23.
694. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.
作者: Peter Malfertheiner.;Viola Schultze.;Bernd Rosenkranz.;Stefan H E Kaufmann.;Timo Ulrichs.;Deborah Novicki.;Francesco Norelli.;Mario Contorni.;Samuele Peppoloni.;Duccio Berti.;Daniela Tornese.;Jitendra Ganju.;Emanuela Palla.;Rino Rappuoli.;Bruce F Scharschmidt.;Giuseppe Del Giudice.
来源: Gastroenterology. 2008年135卷3期787-95页
Helicobacter pylori infection is among the most common human infections and the major risk factor for peptic disease and gastric cancer. Immunization with vaccines containing the H pylori vacuolating cytotoxin A (VacA), cytotoxin-associated antigen (CagA), and neutrophil-activating protein (NAP), alone or in combination, have been shown to prevent experimental infection in animals.
695. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
作者: Bruce E Sands.;William J Sandborn.;Brian Feagan.;Robert Löfberg.;Toshifumi Hibi.;Tao Wang.;Lisa-Marie Gustofson.;Cindy J Wong.;Margaret K Vandervoort.;Stephen Hanauer.; .
来源: Gastroenterology. 2008年135卷2期400-9页
Activated granulocytes and monocytes/macrophages are implicated in the pathogenesis of ulcerative colitis. Open-label studies and clinical experience in Japan and Europe have suggested that granulocyte/monocyte apheresis is safe and effective in treating ulcerative colitis.
696. Combined written and oral information prior to gastrointestinal endoscopy compared with oral information alone: a randomized trial.
作者: Christian Felley.;Thomas V Perneger.;Isabelle Goulet.;Catherine Rouillard.;Nadereh Azar-Pey.;Gian Dorta.;Antoine Hadengue.;Jean-Louis Frossard.
来源: BMC Gastroenterol. 2008年8卷22页
Little is known about how to most effectively deliver relevant information to patients scheduled for endoscopy.
697. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
作者: Vlad Ratziu.;Philippe Giral.;Sophie Jacqueminet.;Fréderic Charlotte.;Agnès Hartemann-Heurtier.;Lawrence Serfaty.;Philippe Podevin.;Jean-Marc Lacorte.;Carole Bernhardt.;Eric Bruckert.;André Grimaldi.;Thierry Poynard.; .
来源: Gastroenterology. 2008年135卷1期100-10页
Nonalcoholic steatohepatitis (NASH) is a liver disease that complicates insulin-resistant states. This trial tested the efficacy and safety of rosiglitazone, an insulin-sensitizing agent, in patients with NASH.
698. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
作者: Peter Ferenci.;Hermann Laferl.;Thomas-Matthias Scherzer.;Michael Gschwantler.;Andreas Maieron.;Harald Brunner.;Rudolf Stauber.;Martin Bischof.;Bernhard Bauer.;Christian Datz.;Karin Löschenberger.;Elisabeth Formann.;Katharina Staufer.;Petra Steindl-Munda.; .
来源: Gastroenterology. 2008年135卷2期451-8页
This analysis reports the rate of sustained virological response (SVR) in patients infected with hepatitis C virus (HCV) genotype 1 or 4 who were assigned to 24 weeks of treatment with pegylated interferon (peginterferon) alfa-2a 180 mug/wk plus ribavirin 1000/1200 mg/day after achieving a rapid virological response (RVR; HCV RNA level <50 IU/mL) at week 4 in a prospective trial investigating response-guided therapy.
699. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux.
作者: Zongli Zheng.;Karen L Margolis.;Simin Liu.;Lesley F Tinker.;Weimin Ye.; .
来源: Gastroenterology. 2008年135卷1期72-81页
An association between female hormones and symptomatic gastroesophageal reflux disease (GERD) and may be modified by obesity is suggested but not proven. Factors affecting GERD progression, however, are largely unknown.
700. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
作者: Leo G van Rossum.;Anne F van Rijn.;Robert J Laheij.;Martijn G van Oijen.;Paul Fockens.;Han H van Krieken.;Andre L Verbeek.;Jan B Jansen.;Evelien Dekker.
来源: Gastroenterology. 2008年135卷1期82-90页
Despite poor performance, guaiac-based fecal occult blood tests (G-FOBT) are most frequently implemented for colorectal cancer screening. Immunochemical fecal occult blood tests (I-FOBT) are claimed to perform better, without randomized comparison in screening populations. Our aim was to randomly compare G-FOBT with I-FOBT in a screening population.
|